372 related articles for article (PubMed ID: 9788619)
1. Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1.
Krystal GW; DeBerry CS; Linnekin D; Litz J
Cancer Res; 1998 Oct; 58(20):4660-6. PubMed ID: 9788619
[TBL] [Abstract][Full Text] [Related]
2. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells.
Krystal GW; Honsawek S; Kiewlich D; Liang C; Vasile S; Sun L; McMahon G; Lipson KE
Cancer Res; 2001 May; 61(9):3660-8. PubMed ID: 11325836
[TBL] [Abstract][Full Text] [Related]
3. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth.
Krystal GW; Honsawek S; Litz J; Buchdunger E
Clin Cancer Res; 2000 Aug; 6(8):3319-26. PubMed ID: 10955819
[TBL] [Abstract][Full Text] [Related]
4. Src family kinase activity is required for Kit-mediated mitogen-activated protein (MAP) kinase activation, however loss of functional retinoblastoma protein makes MAP kinase activation unnecessary for growth of small cell lung cancer cells.
Bondzi C; Litz J; Dent P; Krystal GW
Cell Growth Differ; 2000 Jun; 11(6):305-14. PubMed ID: 10910097
[TBL] [Abstract][Full Text] [Related]
5. Induction of apoptosis and inhibition of small cell lung cancer growth by the quinoxaline tyrphostins.
Krystal GW; Carlson P; Litz J
Cancer Res; 1997 Jun; 57(11):2203-8. PubMed ID: 9187122
[TBL] [Abstract][Full Text] [Related]
6. Early myeloid cells expressing c-KIT isoforms differ in signal transduction, survival and chemotactic responses to Stem Cell Factor.
Young SM; Cambareri AC; Odell A; Geary SM; Ashman LK
Cell Signal; 2007 Dec; 19(12):2572-81. PubMed ID: 17855052
[TBL] [Abstract][Full Text] [Related]
7. An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies.
He H; Hirokawa Y; Levitzki A; Maruta H
Cancer J; 2000; 6(4):243-8. PubMed ID: 11038144
[TBL] [Abstract][Full Text] [Related]
8. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor.
Krystal GW; Hines SJ; Organ CP
Cancer Res; 1996 Jan; 56(2):370-6. PubMed ID: 8542594
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
10. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
11. Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells.
Amoui M; Dráber P; Dráberová L
Eur J Immunol; 1997 Aug; 27(8):1881-6. PubMed ID: 9295022
[TBL] [Abstract][Full Text] [Related]
12. Src family kinase inhibitors block amphiregulin-mediated autocrine ErbB signaling in normal human keratinocytes.
Kansra S; Stoll SW; Johnson JL; Elder JT
Mol Pharmacol; 2005 Apr; 67(4):1145-57. PubMed ID: 15615697
[TBL] [Abstract][Full Text] [Related]
13. Src family tyrosine kinases participate in insulin-like growth factor I mitogenic signaling in 3T3-L1 cells.
Boney CM; Sekimoto H; Gruppuso PA; Frackelton AR
Cell Growth Differ; 2001 Jul; 12(7):379-86. PubMed ID: 11457735
[TBL] [Abstract][Full Text] [Related]
14. Lck is involved in interleukin-2 induced proliferation but not cell survival in human T cells through a MAP kinase-independent pathway.
Brockdorff J; Nielsen M; Kaltoft K; Mustelin T; Röpke C; Svejaard A; Geisler C; Odum N
Eur Cytokine Netw; 2000 Jun; 11(2):225-31. PubMed ID: 10903801
[TBL] [Abstract][Full Text] [Related]
15. Plasminogen activator inhibitor type-1 gene expression and induced migration in TGF-beta1-stimulated smooth muscle cells is pp60(c-src)/MEK-dependent.
Samarakoon R; Higgins CE; Higgins SP; Kutz SM; Higgins PJ
J Cell Physiol; 2005 Jul; 204(1):236-46. PubMed ID: 15622520
[TBL] [Abstract][Full Text] [Related]
16. Suppression of CD4+ T cell activation by a novel inhibitor of Src family kinases.
McRae BL; Wallace C; Dixon KF; Roux A; Mohan S; Jia Y; Presky DH; Tracey DE; Hirst GC
Int Immunopharmacol; 2005 Apr; 5(4):667-77. PubMed ID: 15710336
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
Wolff NC; Randle DE; Egorin MJ; Minna JD; Ilaria RL
Clin Cancer Res; 2004 May; 10(10):3528-34. PubMed ID: 15161712
[TBL] [Abstract][Full Text] [Related]
18. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
19. The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases.
Tatton L; Morley GM; Chopra R; Khwaja A
J Biol Chem; 2003 Feb; 278(7):4847-53. PubMed ID: 12475982
[TBL] [Abstract][Full Text] [Related]
20. Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling.
Khanzada UK; Pardo OE; Meier C; Downward J; Seckl MJ; Arcaro A
Oncogene; 2006 Feb; 25(6):877-87. PubMed ID: 16170339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
